Compare Abeona Therapeutics Inc (ABEO) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Schwab US Large Cap Growth ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Schwab US Large Cap Growth ETF trades at $34.15. Which is the better fit depends on your goals.
| ABEO | SCHG | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $35.30 |
52-Week Low | $4.17 | $28.10 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SCHG, the Schwab U.S. Large-Cap Growth ETF, trades at $34.53, up 1.2% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides concentrated exposure to large-cap growth stocks, particularly in technology, with top holdings like Nvidia, Apple, and Microsoft. Recent news highlights its positioning to benefit from AI-driven capital expenditure growth, though some analysts note concentration risks.
The outlook for SCHG is supported by strong AI adoption trends and institutional inflows, but risks include high portfolio concentration and sensitivity to interest rate changes. Valuation remains elevated, with a portfolio P/E around 32x, which could pressure returns if growth expectations moderate. Investors should weigh the growth potential against these concentration and macroeconomic risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
